NCT04818723

Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Syndrome

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Nishtar Medical University · Academic / Other
• Sex: All
• Age: 1 Year – 10 Years
• Healthy volunteers: Not accepted

Summary

The investigators planned this research to elucidate if there is any efficacy of montelukast, a leukotriene receptor antagonist, in steroid sensitive childhood onset NS to help prevent relapses. This study was done to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)

Detailed description

A quasi-experimental study, done at Department of Pediatric Nephrology at the Children's Hospital \& the Institute of Child Health, Multan. A total of 96 patients aged 1-10 years with steroid sensitive Idiopathic NS were assigned into two groups (48 patients in each group). The case group received montelukast 5mg daily at bed time while the control group was not given montelukast. Steroid treatment protocol was the same for the two groups as per institutional guidelines. Patients were monitored and followed for the response to treatment and evidence of relapse over the study period (minimum 12 months).

Conditions

• Nephrotic Syndrome

Interventions

Type	Name	Description
DRUG	Montelukast	We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)

Timeline

• Start date: 2019-02-01
• Primary completion: 2020-05-30
• Completion: 2020-05-30
• First posted: 2021-03-26
• Last updated: 2021-03-26

Locations

1 site across 1 country: Pakistan